Farah was tested six days after the injection 17 April 2014
Hypoglycaemia (low blood sugar) is another consideration, particularly for people with epilepsy who also have diabetes and take insulin or sulphonylureas
For comparison, Sermorelin another GHRH analog available through compounding pharmacies works through a similar mechanism but has a shorter half-life, less clinical data, and no FDA approval
Type 2 diabetes (T2D) is often comorbid with NAFLD, and increases the risk for rapid progression to NASH and cirrhosis (Targher et al., 2021)
Tirzepatide, having received FDA approval, has a more defined safety record, though patients should be monitored for potential risks such as pancreatitis or thyroid tumors, which have been concerns with GLP-1 receptor agonists in general
Why is Cagrilintide studied